TickerTalks
Browse all tickers →
TickerTalks›$GSK
GSGSK

GSK plc

$GSK·$104B·Drug Manufacturers - General·Healthcare
$52.05+1.4%YTD+4.3%1Y+34.3%
Mentions · last 7 days
2026-07-20: 6 posts2026-07-21: 8 posts2026-07-22: 23 posts2026-07-23: 21 posts2026-07-24: 17 posts2026-07-25: 15 posts2026-07-26: 16 posts106+25%
Price updated 12m ago·X counts updated 21h ago
GSGSK
$GSKGSK plc
$52.05+1.35%106 posts+25%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $GSK, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersEvent coming upAI verdict · as of 2026-07-26

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

GSK just landed early FDA approval for Jideytro in ROS1+ NSCLC — up 34% over 12 months, into 7/28 earnings.

GSK plc is a global pharma with a large HIV, oncology, respiratory, and vaccine franchise — plus a strategic partnership with Nuvation Bio (NUVL) that just paid off with a Jideytro (zidesamtinib) approval. Up 34% over 12 months and 4% YTD, this is a mega-cap compounder into 7/28 earnings.

The setup is a real business with a fresh regulatory catalyst:

  • Revenue growth is modest: Q1 revenue grew 1.5% YoY to $7.6B with a 75% gross margin and 30% operating margin — the durable pharma economics are intact, and the last four EPS prints all beat by 6-17%.
  • The Jideytro approval is genuine catalyst: 7/23 early FDA approval for ROS1-selective inhibitor in previously-treated ROS1+ NSCLC — ahead of the September 18 PDUFA date, and the first GSK approval in the ROS1 space via the Nuvation Bio partnership.
  • The pipeline economics are real: $11B ALK acquisition context, plus specialty medicines growth is what management will highlight on 7/28 — though the decision not to progress camlipixant in refractory chronic cough is a partial disappointment.

At 59% of the 52-week range and near both moving averages, the tape is coiled ahead of 7/28. A revenue beat plus specialty-medicines-growth commentary restarts the trade higher; a soft respiratory-franchise print or a pipeline-attrition disclosure extends the coil despite the fresh Jideytro approval.

Agrees with X sentimentX is right on the early Jideytro FDA approval for ROS1+ NSCLC (ahead of Sept 18 PDUFA), the GSK-Nuvation Bio partnership paying off much earlier than expected, and the $11B ALK acquisition context. The camlipixant discontinuation as 'surprising' is a fair partial disagreement — a real pipeline setback in an otherwise-strong week.

What to watch: 7/28 Q2 earnings — a revenue beat plus specialty-medicines-growth commentary restarts the trade higher; a soft respiratory-franchise print or pipeline-attrition disclosure extends the coil.

On the calendar: 2026-07-28 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment7 posts analyzed · as of 2026-07-25

GSK landed early FDA approval for Jideytro (zidesamtinib) — a ROS1-selective inhibitor for previously treated ROS1+ non-small cell lung cancer, ahead of the Sept 18 PDUFA and backed by ARROS-1 Ph1/2 data. It's the first GSK approval in the space. The GSK x Nuvation Bio ($NUVL) partnership is paying off much earlier than anticipated. GSK's $11B ALK acquisition deal is being contextualized alongside TNGX's opportunity in double RAS/MTAP lung cancer. GSK's decision not to progress camlipixant in refractory chronic cough was 'surprising.' Direction is decisively long the FDA approval catalyst.

Read the AI verdict + X sentiment for $GSK

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

UK-based global pharma company developing vaccines and specialty medicines across infectious disease, HIV, respiratory, oncology, and immunology.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $GSK.

Drug Manufacturers - General · Healthcare

No material change from last week — oral semaglutide versus injectable Zepbound, with Amgen, Pfizer, and AZ all presenting obesity pipeline data.

What this means for $GSK

Neutral — UK-based global pharma company developing vaccines and specialty medicines across infectious disease, HIV, respiratory, oncology, and immunology; limited read-through from drug manufacturers - general macro dynamics to this specific revenue mix.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+20.4%YTD
+47.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
13.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
13.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
22.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
35.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
72.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 29, 2026$1.24$1.16+6.9%
Q4 2025Feb 4, 2026$0.68$0.64+6.3%
Q3 2025Oct 29, 2025$1.48$1.26+17.5%
Q2 2025Jul 30, 2025$1.23$1.12+9.8%
Next earningsTue, Jul 28·consensus EPS $1.27

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$7.6B+1.5%75.4%30.1%$0.86$698.0M
Q4 FY25$8.6B+6.2%69.2%17.5%$0.84$1.5B
Q3 FY25$8.5B+6.7%73.6%30.3%$1.00$2.6B
Q2 FY25$8.0B+1.3%72.9%25.3%$0.72$1.5B

Forward consensus

5-year forecast · up to 17 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$34.0B$33.7B – $34.2B$3.58$3.48 – $3.6913
FY27$35.7B$33.4B – $36.8B$3.92$3.69 – $4.1413
FY28$36.9B$35.8B – $37.9B$4.12$3.89 – $4.4317
FY29$38.4B$37.3B – $39.5B$4.33$4.17 – $4.4914
FY30$37.9B$36.9B – $39.0B$4.40$4.24 – $4.568

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.59%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-0.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-0.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 1.9B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.305-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

No material 8-K / SC 13D / S-3 / 424B5 filings in the last 180 days.

+ 181 other (162 6-Ks · 6 SC TO-T/As · 3 SC TO-Cs · 2 SC TO-Ts) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Bank of New York Mellon Corp Reduces Holdings in GSK PLC Sponsored ADR $GSKdefenseworld.net·3d agoFTSE 100 shares to watch: Lloyds, Barclays, IAG, NatWest, GSK, AstraZenecainvezz.com·4d agoSMMT Shares Updated Ivonescimab Survival Data From NSCLC Studyzacks.com·4d agoGSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLCzacks.com·4d agoWill GSK's Specialty Medicines Boost Q2 Revenue Growth?zacks.com·4d ago

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LLY$NVO$JNJ$PFE$MRK$ABBV$BMY$AZN
Voices on X · top 6 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport